COMPARISON

Vancomycin vs Vasopressin

3 attributes held for at least one of the two. 2 differ. Each value carries the register it came from and the date that register was read.

Answer

Vancomycin is authorised or registered in 9 and Vasopressin in 7 of the 10 registers read. Vancomycin: highest phase Phase 4 (after approval). Vasopressin: highest phase Phase 4 (after approval). 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

VancomycinVasopressin
Registered trials
differs
738
clinicaltrials.gov · 2026-10-03
449
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA-approved: Vancomycin Hydrochloride
openfda · 2026-10-03T17:23:44.062Z
FDA-approved: VASOPRESSIN
openfda · 2026-10-03T17:23:44.062Z
EU authorisation
Nothing on record
ema read 2026-08-31
Nothing on record
ema read 2026-08-31

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectVancomycinplaceboVasopressinplacebo
Cough16.1%12.3%--
Headache5.8%6.4%--
Nausea5.0%5.3%--
Pyrexia5.0%4.4%--
Diarrhoea4.7%4.8%--
Vomiting2.3%5.2%--

Trial register Vancomycin: 5 placebo-controlled trials; Vasopressin: 3. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Vancomycin side effects · Vasopressin side effects

LEGAL STATUS

Approval in each country read

CountryVancomycinVasopressinRegister
United StatesFDA-approvedFDA-approvedRegulator FDA
European UnionNot on the registerNot on the registerRegulator EMA
United KingdomAuthorisedAuthorisedRegulator MHRA
CanadaAuthorisedAuthorisedRegulator Health Canada
AustraliaRegisteredStatus unknownRegulator TGA
SwitzerlandAuthorisedAuthorisedRegulator Swissmedic
BrazilRegistadoRegistadoRegulator ANVISA
SerbiaAuthorisedNot on the registerRegulator ALIMS
SingaporeRegisteredRegisteredRegulator HSA
TurkeyRuhsatliRuhsatliRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.